JP2007529544A - 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩 - Google Patents

3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩 Download PDF

Info

Publication number
JP2007529544A
JP2007529544A JP2007504115A JP2007504115A JP2007529544A JP 2007529544 A JP2007529544 A JP 2007529544A JP 2007504115 A JP2007504115 A JP 2007504115A JP 2007504115 A JP2007504115 A JP 2007504115A JP 2007529544 A JP2007529544 A JP 2007529544A
Authority
JP
Japan
Prior art keywords
dsb
salt
pharmaceutical composition
administered
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007504115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529544A5 (cg-RX-API-DMAC7.html
Inventor
マーティン・デイル・パワー
デイビッド・ユージーン・マーティン
Original Assignee
パナコス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パナコス ファーマシューティカルズ, インコーポレイテッド filed Critical パナコス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2007529544A publication Critical patent/JP2007529544A/ja
Publication of JP2007529544A5 publication Critical patent/JP2007529544A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007504115A 2004-03-17 2005-03-17 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩 Pending JP2007529544A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55355404P 2004-03-17 2004-03-17
US58467404P 2004-07-02 2004-07-02
PCT/US2005/008935 WO2005090380A1 (en) 2004-03-17 2005-03-17 Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid

Publications (2)

Publication Number Publication Date
JP2007529544A true JP2007529544A (ja) 2007-10-25
JP2007529544A5 JP2007529544A5 (cg-RX-API-DMAC7.html) 2008-05-08

Family

ID=34993638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504115A Pending JP2007529544A (ja) 2004-03-17 2005-03-17 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩

Country Status (11)

Country Link
US (2) US20050239748A1 (cg-RX-API-DMAC7.html)
EP (1) EP1730163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007529544A (cg-RX-API-DMAC7.html)
AU (1) AU2005224260A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0508854A (cg-RX-API-DMAC7.html)
CA (1) CA2560266A1 (cg-RX-API-DMAC7.html)
IL (1) IL178128A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06010592A (cg-RX-API-DMAC7.html)
NO (1) NO20064676L (cg-RX-API-DMAC7.html)
RU (1) RU2387665C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005090380A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009120516A (ja) * 2007-11-13 2009-06-04 Tokyo Medical Univ 抗ウィルス剤
JP2013527242A (ja) * 2010-06-04 2013-06-27 ブリストル−マイヤーズ スクイブ カンパニー Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
JP2019524724A (ja) * 2016-07-15 2019-09-05 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ テコビリマットの経口用医薬組成物及びその調製法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610668A2 (pt) * 2005-04-12 2010-07-13 Panacos Pharmaceuticals Inc polimorfas de di-n-metil-d-glucamina do ácido 3-o-(3',3'-dimetilsuccinil) betulìnico
ZA200805703B (en) * 2005-12-16 2009-10-28 Panacos Pharmaceuticals Inc Preparation of pharmaceutical salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
WO2008057420A2 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
WO2012106190A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
BR112012030810A2 (pt) 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
US20140221328A1 (en) * 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
EP2758419B8 (en) 2011-09-21 2017-04-19 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
EA027371B1 (ru) 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX374543B (es) 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
AU2015346303B2 (en) 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN107625967B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
WO2020006510A1 (en) 2018-06-29 2020-01-02 Dfh Therapeutics Triterpene amine derivatives
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843976A (ja) * 1981-08-21 1983-03-14 ブリストル―マイヤーズ スクイブ カンパニー N−メチル−d−グルカミン塩
JPS60163897A (ja) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
JP2000512988A (ja) * 1996-06-27 2000-10-03 コブラ セラピューティクス リミテッド ケルセチンのアナログまたは誘導体(プロドラッグ)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
US4205073A (en) * 1975-04-30 1980-05-27 Schering Corporation Anti-diarrheal anilino nicotinic acids and method of using same
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
WO1993007904A1 (en) * 1991-10-16 1993-04-29 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
NZ506623A (en) * 1998-03-02 2002-10-25 Univ North Carolina Acylated betulin and dihydrobetulin derivatives, preparation thereof and use in treatment of retroviral infections
JP2002518521A (ja) * 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
US6579828B1 (en) * 1999-10-15 2003-06-17 Nippon Paper Industries Co. Ltd Multi chromatic thermally sensitive recording medium
CA2406562C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US7365221B2 (en) * 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
AU2004210162A1 (en) * 2003-01-29 2004-08-19 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
EP1675866A1 (en) * 2003-09-26 2006-07-05 Panacos Pharmaceuticals, Inc. Novel triterpene derivatives, preparation thereof and use thereof
RU2243233C1 (ru) * 2003-12-24 2004-12-27 Московская государственная академия тонкой химической технологии им. М.В. Ломоносова Производные бетулина как ингибиторы комплемента

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843976A (ja) * 1981-08-21 1983-03-14 ブリストル―マイヤーズ スクイブ カンパニー N−メチル−d−グルカミン塩
JPS60163897A (ja) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
JP2000512988A (ja) * 1996-06-27 2000-10-03 コブラ セラピューティクス リミテッド ケルセチンのアナログまたは誘導体(プロドラッグ)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009120516A (ja) * 2007-11-13 2009-06-04 Tokyo Medical Univ 抗ウィルス剤
JP2013527242A (ja) * 2010-06-04 2013-06-27 ブリストル−マイヤーズ スクイブ カンパニー Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
JP2019524724A (ja) * 2016-07-15 2019-09-05 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ テコビリマットの経口用医薬組成物及びその調製法
US11318115B2 (en) 2016-07-15 2022-05-03 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Oral pharmaceutical composition of Tecovirimat and preparation method thereof

Also Published As

Publication number Publication date
MXPA06010592A (es) 2007-06-12
EP1730163A4 (en) 2009-12-30
WO2005090380A1 (en) 2005-09-29
NO20064676L (no) 2006-12-01
IL178128A0 (en) 2006-12-31
BRPI0508854A (pt) 2007-08-28
RU2006136409A (ru) 2008-04-27
US20050239748A1 (en) 2005-10-27
CA2560266A1 (en) 2005-09-29
EP1730163A1 (en) 2006-12-13
AU2005224260A1 (en) 2005-09-29
RU2387665C2 (ru) 2010-04-27
US20120214775A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
RU2387665C2 (ru) Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
US7365221B2 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
CN108245496B (zh) 虾青素抗炎增效组合
JP2002505337A (ja) アシル化ベツリンおよびジヒドロベツリンの誘導体、その調製物、およびそれらの使用
US20040131629A1 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050148561A1 (en) Novel triterpene derivatives, preparation thereof and use thereof
US20210060034A1 (en) The Pharmaceutical Composition Intended to Inhibit HIV Infectivity in Order to Treat the Acquired Immune Deficiency Syndrome (AIDS) and Its Complications
US7799768B2 (en) Polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine
JP7576336B2 (ja) 16α-ブロモ-3β-ヒドロキシ-5α-アンドロスタン-17-ケトンおよびその水和物、誘導体および類似体を含む水性懸濁液組成物、製剤および水分散性乾燥組成物
CN100591688C (zh) 3-0-(3',3'-二甲基琥珀酰基)桦木酸的药用盐
KR20070031888A (ko) 3-0-(3',3'-다이메틸숙시닐)베툴린산의 약리학적염
ZA200602758B (en) Novel triterpene derivatives, preparation thereof and use thereof
KR101926871B1 (ko) 인체면역결핍바이러스의 예방 또는 치료용 약제학적 조성물
MXPA06003252A (en) Novel triterpene derivatives, preparation thereof and use thereof
WO2008054250A1 (en) N'-{n-[3-oxo-lupen-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropeonic acid and the pharmaceutically acceptable derivatives thereof, a method for the production and the use thereof in the form of a medicinal agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101